蛛网膜下腔出血与COVID-19:282718例患者分析
基于Cerner去标识COVID-19数据集62家医疗机构分析,COVID-19患者SAH风险未增加(OR 0.5,95%CI 0.4-0.7,P<0.0001);但SAH合并COVID-19者肺炎、急性肾损伤、脓毒性休克、呼吸衰竭比例及院内死亡率均显著更高。
要点
- COVID-19患者SAH风险未增加,校正后OR 0.5(95%CI 0.4-0.7)。
- SAH合并COVID-19者院内死亡率31.4%,显著高于无COVID-19者12.2%。
- 死亡升高可能与肺炎、急性肾损伤、脓毒性休克、呼吸衰竭等系统性合并症更常见有关。
核心结论
- COVID-19患者发生SAH的风险未增加。
- SAH合并COVID-19患者院内死亡率显著高于无COVID-19的SAH患者,可能由系统性合并症更高频介导。
研究设计与样本
- 基于Cerner去标识COVID-19数据集、纳入62家医疗机构数据的分析。
- 比较85,645例COVID-19患者与197,073例无COVID-19患者的SAH发生情况。
主要发现
- COVID-19患者中SAH 86例(0.1%),无COVID-19患者中SAH 376例(0.2%)。
- 多变量模型校正性别、年龄分层、种族/民族、高血压和尼古丁依赖/烟草使用后,COVID-19患者SAH风险更低(OR 0.5,95%CI 0.4-0.7,P<0.0001)。
- SAH合并COVID-19患者肺炎比例58.1% vs 21.3%(P<0.0001)。
- SAH合并COVID-19患者急性肾损伤43% vs 27.7%(P=0.0005)、脓毒性休克44.2% vs 20.7%(P<0.0001)、呼吸衰竭64.0% vs 39.1%(P<0.0001)。
- SAH合并COVID-19患者院内死亡率31.4% vs 12.2%(P<0.0001)。
临床怎么用
- 对COVID-19患者不应将SAH风险增加作为常规预判。
- SAH合并COVID-19患者需重点关注肺炎、急性肾损伤、脓毒性休克和呼吸衰竭等系统性合并症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intracranial hemorrhage (including subarachnoid hemorrhage [SAH]) has been reported in 0.3%-1.2% of patients with coronavirus disease 2019 (COVID-19). However, no study has evaluated the risk of SAH in patients with COVID-19. METHODS: We analyzed data from 62 health care facilities using the Cerner de-identified COVID-19 dataset. RESULTS: There were 86 (0.1%) and 376 (0.2%) patients with SAH among 85,645 patients with COVID-19 and 197,073 patients without COVID-19, respectively. In the multivariate model, there was a lower risk of SAH in patients with COVID-19 (odds ratio 0.5, 95% confidence interval 0.4-0.7, P < 0.0001) after adjusting for sex, age strata, race/ethnicity, hypertension, and nicotine dependence/tobacco use. The proportions of patients who developed pneumonia (58.1% vs. 21.3%, P < 0.0001), acute kidney injury (43% vs. 27.7%, P = 0.0005), septic shock (44.2% vs. 20.7%, P < 0.0001), and respiratory failure (64.0% vs. 39.1%, P < 0.0001) were significantly higher among patients with SAH and COVID-19 compared with patients without COVID-19. The in-hospital mortality among patients with SAH and COVID-19 was significantly higher compared with patients without COVID-19 (31.4% vs. 12.2%, P < 0.0001). CONCLUSIONS: The risk of SAH was not increased in patients with COVID-19. The higher mortality in patients with SAH and COVID-19 compared with patients without COVID-19 is likely mediated by higher frequency of systemic comorbidities.
引用
- Qureshi AI, Baskett WI, Huang W, et al. Subarachnoid Hemorrhage and COVID-19: An Analysis of 282,718 Patients. World Neurosurg. 2021. PMID: 33940263. doi:10.1016/j.wneu.2021.04.089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。